How Parkinson's Disease Is Diagnosed

Parkinson's disease is diagnosed clinically, based on a thorough neurological examination, detailed medical history, the pattern and progression of symptoms, and the patient's response to Parkinson's medications. There is no single blood test, brain scan, or laboratory marker that can definitively confirm the diagnosis on its own. The most widely accepted framework is the 2015 MDS Clinical Diagnostic Criteria, which require bradykinesia plus at least one additional motor sign, along with supportive features and the absence of exclusion criteria. Evaluation by a movement disorder specialist is strongly recommended.

Why Diagnosis Can Be Challenging

Parkinson's disease shares motor features with several other conditions, and its early symptoms can be subtle, asymmetric, and nonspecific. Studies have shown that even experienced neurologists misdiagnose the condition in approximately 10 to 25 percent of cases, particularly in early stages when symptoms are mild. Misdiagnosis rates are highest when evaluation is performed by non-specialists — one community-based study found that up to 47 percent of patients initially diagnosed with PD by primary care physicians had their diagnosis revised upon specialist evaluation.

This diagnostic uncertainty underscores why evaluation by a movement disorder specialist — a neurologist with fellowship training in Parkinson's and related conditions — is the gold standard. These specialists see hundreds of PD patients annually and are trained to detect subtle motor signs, differentiate between look-alike conditions, and apply diagnostic criteria with precision.

The Clinical Examination

The neurological examination is the cornerstone of Parkinson's diagnosis. A movement disorder specialist will systematically assess the following:

• Bradykinesia (slowness of movement). The doctor will ask you to perform repetitive movements — tapping your finger and thumb together, opening and closing your hand, or tapping your foot — and look for slowness, hesitation, arrests (brief freezes mid-motion), and a progressive decrease in amplitude (movements getting smaller with each repetition). This progressive decrement is characteristic of PD and helps distinguish it from other causes of slowness. Bradykinesia is the single required feature for a Parkinson's diagnosis.
• Tremor. The doctor will observe your hands while they rest in your lap, during mental distraction tasks (like counting backwards from 100 by 7s, which often brings out subtle tremor), and during sustained posture (arms extended). Resting tremor at 4-6 Hz is the most characteristic tremor in PD.
• Rigidity. The examiner will gently move your arms, wrists, neck, and legs to feel for increased resistance to passive movement. “Cogwheel rigidity,” a ratcheting sensation during passive movement, is a common finding caused by superimposed tremor on rigidity. The “Froment maneuver” — asking you to perform a movement with one hand while the examiner tests the other — can bring out subtle rigidity.
• Gait and posture. You will be asked to walk across the room, turn, and come back. The doctor will look for shuffling steps, reduced arm swing (often asymmetric), stooped posture, en bloc turning (turning the body as a unit rather than head-first), and festination (involuntary acceleration of gait). A “pull test” — a firm, unexpected tug backward at the shoulders — checks postural reflexes.
• Facial expression. Hypomimia (reduced facial expression, reduced blink rate) is assessed during the interview and examination.
• Speech. The examiner will note voice volume, articulation, and prosody (the rhythm and intonation of speech). Hypophonia (soft voice) and monotone speech are common early findings.

MDS Clinical Diagnostic Criteria (2015)

The most widely accepted diagnostic framework is the Movement Disorder Society (MDS) Clinical Diagnostic Criteria for Parkinson's Disease, published in 2015. This system replaced earlier clinical criteria and is used by movement disorder specialists worldwide. It establishes two levels of diagnostic certainty: clinically established PD and clinically probable PD.

Step 1: Parkinsonism Must Be Present

The foundation of diagnosis is the presence of parkinsonism, defined as bradykinesia plus at least one of the following: resting tremor, rigidity, or both. Bradykinesia must be demonstrated — not just reported — and must show the characteristic progressive decrement in speed or amplitude with repetitive movements.

Step 2: Supportive Criteria

Features that increase confidence in the diagnosis include:

• Clear and dramatic beneficial response to dopaminergic therapy (typically levodopa)
• Presence of levodopa-induced dyskinesia
• Rest tremor of a limb documented on clinical examination
• Positive results on olfactory testing (loss of smell) or cardiac sympathetic denervation on MIBG scintigraphy

Step 3: Absolute Exclusion Criteria

Certain findings definitively rule out Parkinson's disease:

• Unequivocal cerebellar abnormalities (ataxia, cerebellar oculomotor abnormalities)
• Downward vertical supranuclear gaze palsy (hallmark of progressive supranuclear palsy)
• Diagnosis of behavioral variant frontotemporal dementia or primary progressive aphasia within the first 5 years
• Parkinsonian features restricted to the lower limbs for more than 3 years (suggests vascular parkinsonism)
• Treatment with a dopamine receptor blocker at a dose and time-course consistent with drug-induced parkinsonism
• Absence of any response to high-dose levodopa despite at least moderate disease severity
• Unequivocal cortical sensory loss, limb ideomotor apraxia, or progressive aphasia
• Normal dopamine transporter imaging (normal DaTscan)

Step 4: Red Flags

Red flags are features that suggest an alternative diagnosis. Their presence does not automatically exclude PD, but each red flag must be counterbalanced by a supportive criterion. Red flags include:

• Rapid progression to wheelchair dependence within 5 years of onset
• Complete absence of progression of motor symptoms over 5 or more years
• Early severe autonomic failure (orthostatic hypotension, urinary retention)
• Recurrent falls within the first 3 years
• Disproportionate anterocollis (involuntary forward flexion of the neck) or contractures of hands or feet within the first 10 years
• Absence of any common non-motor features (sleep dysfunction, autonomic dysfunction, hyposmia, or psychiatric features) despite 5 years of disease
• Otherwise unexplained pyramidal tract signs
• Bilateral symmetric parkinsonism from onset

Diagnostic Certainty Levels

The criteria establish two confidence levels:

• Clinically established Parkinson's disease: Parkinsonism is present, no absolute exclusion criteria or red flags are present, and at least two supportive criteria are met.
• Clinically probable Parkinson's disease: Parkinsonism is present, no absolute exclusion criteria are present, and red flags (if present) are counterbalanced by supportive criteria.

Response to Levodopa

One of the strongest supportive features in diagnosing Parkinson's disease is a clear, robust response to levodopa (the dopamine precursor, typically given in combination with carbidopa). Because Parkinson's is fundamentally a disease of dopamine deficiency, most patients experience significant improvement in motor symptoms when dopamine is replaced. The MDS criteria define a “clear and dramatic” response as at least a 30 percent improvement on the MDS-UPDRS Part III (motor examination) or a clear, obvious improvement from the patient's perspective.

A levodopa challenge test is sometimes performed diagnostically: a single, supratherapeutic dose of levodopa/carbidopa is given, and the motor examination is repeated after absorption. A clear response strongly supports the diagnosis. If a patient does not respond meaningfully to adequate doses of levodopa, the diagnosis of Parkinson's disease should be reconsidered. Poor levodopa response is one of the most important signals that an alternative diagnosis — such as progressive supranuclear palsy (PSP), multiple system atrophy (MSA), or corticobasal degeneration (CBD) — may be more appropriate.

Imaging and Laboratory Tests

While no imaging test alone can diagnose Parkinson's disease, several tools provide valuable supporting evidence or help rule out other conditions.

DaTscan (Dopamine Transporter SPECT Imaging)

A DaTscan (also called ioflupane I-123 SPECT) is the most commonly used imaging test in Parkinson's evaluation. It uses a radioactive tracer that binds to dopamine transporters on the surface of presynaptic dopaminergic nerve terminals in the striatum. In Parkinson's disease, the scan shows reduced dopamine transporter density — typically appearing as decreased uptake in one or both sides of the putamen, often with an asymmetric pattern matching the clinically more affected side.

A DaTscan is most useful for distinguishing conditions that involve dopamine neuron loss (Parkinson's disease, MSA, PSP, DLB) from those that do not (essential tremor, drug-induced parkinsonism, psychogenic parkinsonism, dystonic tremor). It cannot distinguish between the different neurodegenerative causes of dopamine loss — all produce abnormal DaTscans — so it is a supportive tool rather than a definitive test. A normal DaTscan is now an absolute exclusion criterion for PD under the MDS criteria.

The procedure takes approximately 3 to 6 hours (including a waiting period for tracer uptake) and involves an injection of the radiotracer followed by a SPECT brain scan. The radiation exposure is comparable to a standard CT scan. Results are typically available within a few days.

MRI of the Brain

A standard MRI is usually normal in Parkinson's disease, which is itself a useful finding. MRI is most valuable for ruling out other causes of parkinsonism:

• Vascular parkinsonism: Small-vessel white matter disease and lacunar infarcts in the basal ganglia
• Normal pressure hydrocephalus: Enlarged ventricles disproportionate to sulcal widening
• Multiple system atrophy: Characteristic findings such as the “hot cross bun” sign in the pons or putaminal atrophy
• Progressive supranuclear palsy: Midbrain atrophy (“hummingbird sign” on sagittal view)
• Structural lesions: Tumors, cysts, or other lesions affecting the basal ganglia

An MRI is not required for PD diagnosis when the clinical picture is classic, but it is often ordered when there is diagnostic uncertainty, atypical features, or when the patient is young.

Blood and Laboratory Tests

No blood test can diagnose Parkinson's disease. Blood work is sometimes ordered to rule out other conditions: thyroid disorders, Wilson's disease (in patients under 50), and medication side effects can all cause symptoms that overlap with parkinsonism. Serum ceruloplasmin and 24-hour urine copper levels are checked when Wilson's disease is considered.

Alpha-Synuclein Seed Amplification Assay (SAA)

A major emerging advance in Parkinson's diagnostics is the alpha-synuclein seed amplification assay (SAA), which detects misfolded alpha-synuclein in cerebrospinal fluid (CSF) obtained via lumbar puncture. Studies have shown that the SAA achieves sensitivity of approximately 87 to 96 percent and specificity of approximately 82 to 96 percent for Parkinson's disease. It can identify PD pathology in prodromal stages, before motor symptoms appear.

The SAA is not yet part of routine clinical practice but is increasingly used in research settings. It is a central component of the proposed NSD-ISS biological definition of Parkinson's disease, which defines the condition based on biomarker evidence of alpha-synuclein pathology rather than clinical symptoms alone. If validated for clinical use, this test could fundamentally change how Parkinson's is diagnosed — enabling earlier detection, more accurate diagnosis, and potentially earlier intervention.

Differential Diagnosis: What Else Could It Be?

Several conditions share features with Parkinson's disease and must be considered during the diagnostic evaluation:

The Diagnostic Timeline: What to Expect

Getting a Parkinson's diagnosis is rarely a single-visit event. The typical process includes:

1. Initial evaluation (visit 1). The specialist takes a detailed history (symptom onset, progression, medications, family history, occupational exposures), performs the neurological examination, and may order blood tests and brain MRI to rule out other conditions. Duration: 60 to 90 minutes.
2. Trial of levodopa (weeks 2-6). If PD is suspected, a trial of levodopa/carbidopa is often started. The patient's response is monitored over several weeks. A clear motor improvement strongly supports the diagnosis.
3. DaTscan (if diagnostic uncertainty). If the clinical picture is unclear — for example, tremor without clear bradykinesia, or symmetric symptoms — a DaTscan may be ordered.
4. Follow-up and reassessment (visit 2, 3-6 months). Early Parkinson's disease can be difficult to confirm on a single visit. A follow-up examination allows the specialist to assess disease evolution. Symptoms that progress and respond to medication increase diagnostic confidence. Sometimes a definitive diagnosis takes 6 to 12 months of observation.

When to Seek Evaluation

If you or a loved one are experiencing unexplained tremor, stiffness, slowness of movement, or changes in handwriting, gait, or facial expression, the first step is to see your primary care physician. If Parkinson's disease is suspected, a referral to a neurologist — ideally a movement disorder specialist — is the most important next step. The Parkinson's Foundation Helpline (1-800-4PD-INFO / 1-800-473-4636) can help locate specialists in your area.

Getting an accurate diagnosis as early as possible matters for several reasons. Early treatment with levodopa and other medications can significantly improve quality of life. Early engagement with exercise and rehabilitation programs has been shown to benefit both motor and non-motor symptoms. Planning for the future — including financial, legal, and care decisions — is best done early, when the person can fully participate. And an accurate diagnosis distinguishes PD from conditions with different prognoses and treatment approaches, preventing unnecessary treatments or missed opportunities.